# Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

> **NCT07155226** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 84 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukaemia
- Acute Myeloid Leukaemia
- Higher-risk Myelodysplastic Syndromes

## Interventions

- **DRUG:** AZD3632
- **DRUG:** Posaconazole

## Key facts

- **NCT ID:** NCT07155226
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2029-02-15
- **Final completion:** 2029-02-15
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155226, "Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07155226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*